The Protective Role of Celastrol in Renal Ischemia-Reperfusion Injury by Activating Nrf2/HO-1, PI3K/AKT Signaling Pathways, Modulating NF-κb Signaling Pathways, and Inhibiting ERK Phosphorylation

Overview

Journal Cell Biochem Biophys

Specialties Biochemistry
Biophysics
Cell Biology

Date 2022 Feb 14

PMID 35157199

Authors

Nancy S Younis

Amal M H Ghanim

Affiliations

Soon will be listed here.

Abstract

Celastrol, a natural triterpenoid derived from Tripterygium wilfordii, possesses numerous biological effects. We investigated celastrol's antioxidant potential through nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) and its effect on phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling, nuclear factor-kappa B (NF-κB) pathways, and extracellular signal-regulated kinase (ERK) activation in kidney ischemia-reperfusion injury (IRI) rat model. Rats were given celastrol 2 mg/kg orally for 1 week before subjection to renal ischemia-reperfusion surgery. Kidney functions, renal MDA, and reduced glutathione were determined; also, renal levels of ERK1/2, HO-1, PI3K, IL-6, TNF-α, IκBα, NF-κB/p65, and cleaved caspase-3 were measured. In addition, gene expression of kidney injury molecule-1 (KIM-1), Nrf-2, and AKT were determined. Celastrol pretreatment attenuated oxidative stress and increased Nrf2 gene expression and HO-1 level. Also, it activated the PI3K/AKT signaling pathway and decreased the p-ERK:t- ERK ratio and NFκBp65 level, with a remarkable decrease in inflammatory cytokines and cleaved caspase-3 levels compared with those in renal IRI rats. Conclusively, celastrol showed a reno-protective potential against renal IRI by suppressing oxidative stress through enhancing the Nrf2/HO-1 pathway, augmenting cell survival PI3K/AKT signaling pathways, and reducing inflammation by inhibiting NF-κB activation.

Citing Articles

Celastrol Mitigates Acetaminophen-Induced Nephrotoxicity in Rats via Targeting Renal Oxidative Stress, Inflammation, Apoptosis with Enhancement in Aquaporin 1 Level.

Ibrahim M, Osman A, Helal A, Faheem A, El-Kattan M, Ibrahim I Rep Biochem Mol Biol. 2025; 13(2):204-217.

PMID: 39995643 PMC: 11847583. DOI: 10.61186/rbmb.13.2.204.

Loss of SAV1 in Kidney Proximal Tubule Induces Maladaptive Repair after Ischemia and Reperfusion Injury.

Moon D, Padanilam B, Park K, Kim J Int J Mol Sci. 2024; 25(9).

PMID: 38731829 PMC: 11083677. DOI: 10.3390/ijms25094610.

A molecular network-based pharmacological study on the protective effect of rhizomes against renal ischemia-reperfusion injury.

Li D, Li N, Cai C, Wei C, Liu G, Wang T Front Pharmacol. 2023; 14:1134408.

PMID: 37144215 PMC: 10151715. DOI: 10.3389/fphar.2023.1134408.

In Silico Analysis of Ferroptosis-Related Genes and Its Implication in Drug Prediction against Fluorosis.

Liu B, Fu X, Du Y, Feng Z, Liu X, Li Z Int J Mol Sci. 2023; 24(4).

PMID: 36835629 PMC: 9961266. DOI: 10.3390/ijms24044221.

Role of PI3K/Akt-Mediated Nrf2/HO-1 Signaling Pathway in Resveratrol Alleviation of Zearalenone-Induced Oxidative Stress and Apoptosis in TM4 Cells.

Xu W, Zheng H, Fu Y, Gu Y, Zou H, Yuan Y Toxins (Basel). 2022; 14(11).

PMID: 36355983 PMC: 9694162. DOI: 10.3390/toxins14110733.

References

Wang Y, Li C, Gu J, Chen C, Duanmu J, Miao J . Celastrol exerts anti-inflammatory effect in liver fibrosis via activation of AMPK-SIRT3 signalling. J Cell Mol Med. 2019; 24(1):941-953. PMC: 6933398. DOI: 10.1111/jcmm.14805. View

Gu L, Bai W, Li S, Zhang Y, Han Y, Gu Y . Celastrol prevents atherosclerosis via inhibiting LOX-1 and oxidative stress. PLoS One. 2013; 8(6):e65477. PMC: 3684610. DOI: 10.1371/journal.pone.0065477. View

Joshi V, Venkatesha S, Ramakrishnan C, Nanjaraj Urs A, Hiremath V, Moudgil K . Celastrol modulates inflammation through inhibition of the catalytic activity of mediators of arachidonic acid pathway: Secretory phospholipase A group IIA, 5-lipoxygenase and cyclooxygenase-2. Pharmacol Res. 2016; 113(Pt A):265-275. DOI: 10.1016/j.phrs.2016.08.035. View

Li H, Zhang Y, Tan H, Jia Y, Li D . Therapeutic effect of tripterine on adjuvant arthritis in rats. J Ethnopharmacol. 2008; 118(3):479-84. DOI: 10.1016/j.jep.2008.05.028. View

Pinna G, Fiorucci M, Reimund J, Taquet N, Arondel Y, Muller C . Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem Biophys Res Commun. 2004; 322(3):778-86. DOI: 10.1016/j.bbrc.2004.07.186. View

Shaker M, Ashamallah S, Houssen M . Celastrol ameliorates murine colitis via modulating oxidative stress, inflammatory cytokines and intestinal homeostasis. Chem Biol Interact. 2014; 210:26-33. DOI: 10.1016/j.cbi.2013.12.007. View

Liu J, Lee J, Hernandez M, Mazitschek R, Ozcan U . Treatment of obesity with celastrol. Cell. 2015; 161(5):999-1011. PMC: 4768733. DOI: 10.1016/j.cell.2015.05.011. View

Kim J, Lee M, Nam D, Song H, Kang Y, Lee J . Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice. PLoS One. 2013; 8(4):e62068. PMC: 3637455. DOI: 10.1371/journal.pone.0062068. View

Sethi G, Ahn K, Pandey M, Aggarwal B . Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood. 2006; 109(7):2727-35. DOI: 10.1182/blood-2006-10-050807. View

10.

Saber S, Ghanim A, El-Ahwany E, Abd El-Kader E . Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis. Cancer Chemother Pharmacol. 2020; 85(2):331-343. DOI: 10.1007/s00280-020-04033-z. View

11.

Shanmugam M, Ahn K, Lee J, Kannaiyan R, Mustafa N, Manu K . Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma. Front Pharmacol. 2018; 9:365. PMC: 5943600. DOI: 10.3389/fphar.2018.00365. View

12.

Tao X, Younger J, Fan F, Wang B, Lipsky P . Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum. 2002; 46(7):1735-43. DOI: 10.1002/art.10411. View

13.

Kitzen J, de Jonge M, Lamers C, Eskens F, van der Biessen D, van Doorn L . Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer. 2009; 45(10):1764-72. DOI: 10.1016/j.ejca.2009.01.026. View

14.

Ge Y, Xie H, Li S, Jin B, Hou J, Zhang H . Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial. J Transl Med. 2013; 11:134. PMC: 3670993. DOI: 10.1186/1479-5876-11-134. View

15.

Ji S, Wang Q, Chen J, Sha G, Liu Z, Li L . Clinical trial of Tripterygium Wilfordii Hook F. in human kidney transplantation in China. Transplant Proc. 2006; 38(5):1274-9. DOI: 10.1016/j.transproceed.2006.03.017. View

18.

Chu C, He W, Kuang Y, Ren K, Gou X . Celastrol protects kidney against ischemia-reperfusion-induced injury in rats. J Surg Res. 2013; 186(1):398-407. DOI: 10.1016/j.jss.2013.07.048. View

19.

Rusai K, Sollinger D, Baumann M, Wagner B, Strobl M, Schmaderer C . Toll-like receptors 2 and 4 in renal ischemia/reperfusion injury. Pediatr Nephrol. 2010; 25(5):853-60. DOI: 10.1007/s00467-009-1422-4. View

20.

Malek M, Nematbakhsh M . Renal ischemia/reperfusion injury; from pathophysiology to treatment. J Renal Inj Prev. 2015; 4(2):20-7. PMC: 4459724. DOI: 10.12861/jrip.2015.06. View

21.

Wu M, Chen W, Yu X, Ding D, Zhang W, Hua H . Celastrol aggravates LPS-induced inflammation and injuries of liver and kidney in mice. Am J Transl Res. 2018; 10(7):2078-2086. PMC: 6079122. View

22.

Liu M, Grigoryev D, Crow M, Haas M, Yamamoto M, Reddy S . Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int. 2009; 76(3):277-85. DOI: 10.1038/ki.2009.157. View